343 Results for "

ABL

" in MedChemExpress (MCE) Product Catalog:
Products (343)

343 Results for "ABL" in MCE Product Catalog:

193
193 Publications Verification
Cat. No.: HY-10181A
CAS No.: 854001-07-3
Purity:  98.86%
Synonyms: BMS-354825 hydrochloride
Research Areas:  

Cancer

Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib hydrochloride also induces apoptosis and autophagy.
loading...
    loading...
193
193 Publications Verification
Cat. No.: HY-10181B
CAS No.: 863127-77-9
Purity:  99.58%
Synonyms: BMS-354825 monohydrate
Research Areas:  

Cancer

Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively . Dasatinib monohydrate also induces apoptosis and autophagy.
loading...
    loading...
193
193 Publications Verification
Cat. No.: HY-10181
CAS No.: 302962-49-8
Purity:  99.83%
Synonyms: BMS-354825
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier .
loading...
    loading...
137
137 Cited Publications
Cat. No.: HY-13520
CAS No.: 31430-18-9
Purity:  99.59%
Synonyms: Oncodazole; R17934
Research Areas:  

Cancer

Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl.
loading...
    loading...
136
136 Cited Publications
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
136
136 Cited Publications
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
72
72 Cited Publications
Cat. No.: HY-15150
CAS No.: 1037624-75-1
Purity:  99.92%
Synonyms: R428; BGB324
Target:  

TAM Receptor

Research Areas:  

Cancer

Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
loading...
    loading...
60
60 Cited Publications
Cat. No.: HY-12047
CAS No.: 943319-70-8
Purity:  99.67%
Synonyms: AP24534
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
60
60 Cited Publications
Cat. No.: HY-108766
CAS No.: 1114544-31-8
Purity:  99.76%
Synonyms: AP24534 hydrochloride
Research Areas:  

Infection Cancer

Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10159A
CAS No.: 923288-90-8
Purity:  99.91%
Synonyms: AMN107 monohydrochloride monohydrate
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against BCR-ABL, and is active against many BCR-ABL mutants.
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10159
CAS No.: 641571-10-0
Purity:  99.94%
Synonyms: AMN107
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10159B
CAS No.: 923288-95-3
Synonyms: AMN107 hydrochloride
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
54
54 Cited Publications
Cat. No.: HY-10159C
Synonyms: AMN107 hydrochloride dihydrate
Target:  

Autophagy Bcr-Abl

Research Areas:  

Cancer

Nilotinib (AMN107) hydrochloride dihydrate is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-13919
CAS No.: 83280-65-3
Purity:  99.94%
Synonyms: BBI608; BB608
Napabucasin (BBI608; BB608) is an orally active STAT3 inhibitor. Napabucasin inhibits STAT3/RelA signaling and induces cancer cell apoptosis, cell cycle arrest, and ROS/DNA damage, inhibiting cancer cell proliferation, migration, and invasion. Napabucasin, upon activation by NQO1/POR, enhances Docetaxel (HY-B0011) sensitivity and inhibits BCR-ABL1-positive leukemia self-renewal. Napabucasin recruits cytotoxic T/B lymphocytes, enhances immune checkpoint blockade, prevents liver metastasis, and radiosensitizes diffuse midline glioma. Napabucasin can be used in research on cancers such as glioblastoma, pancreatic ductal adenocarcinoma, and prostate cancer .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-10158
CAS No.: 380843-75-4
Purity:  99.89%
Synonyms: SKI-606
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-10158A
CAS No.: 918639-08-4
Purity:  99.97%
Synonyms: SKI-606 hydrate
Target:  

Src Bcr-Abl

Research Areas:  

Cancer

Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-13264
CAS No.: 856243-80-6
Purity:  99.70%
Synonyms: WP1130
Research Areas:  

Cancer

Degrasyn (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-104010
CAS No.: 1492952-76-7
Purity:  99.61%
Synonyms: ABL001
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-104010A
CAS No.: 2119669-71-3
Purity:  99.84%
Synonyms: ABL001 hydrochloride
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-50868
CAS No.: 859212-16-1
Synonyms: INNO-406; NS-187
Target:  

Bcr-Abl Src Apoptosis

Research Areas:  

Cancer

Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph + leukemia cells. Bafetinib has antitumor activity .
loading...
    loading...